CTLA4 and cancer: Immune checkpoint inhibitors, such as antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1), have markedly improved cancer patient outcomes, but evoke several adverse effects, which often limit their clinical use (165, 166).